0000917520-26-000044
SEC filingIntegra LifeSciences stockholders at the 2026 Annual Meeting elected all director nominees, ratified PwC as auditors, approved executive compensation advisory vote, and approved Amendment No. 3 to the 2003 Equity Incentive Plan adding 3,550,000 shares.
The 2026 Annual Meeting results reflect strong stockholder alignment with the Board's nominees, auditor selection, and governance proposals. All seven directors received majority approval, with six exceeding 95% support, signaling confidence in current leadership. The overwhelming ratification of PricewaterhouseCoopers LLP ensures continuity in audit oversight. The advisory approval of executive compensation at 97% underscores stockholder endorsement of the pay structure. Critically, the approval of Amendment No. 3 to the 2003 Equity Incentive Plan by approximately 96% increases the Share Limit to 24,250,000 shares, providing capacity for future equity awards to attract and retain key talent amid perceived insufficiency of prior reserves. This amendment, adopted by the Board on April 1, 2026 and effective upon stockholder vote, maintains existing per-employee limits of 2,000,000 shares annually and ISO caps.